angiotensin-receptor blockers

Browse trials
V2  
List  

treatment    comparator  All cause death All cause death Coronary death Coronary event Adverse events Cardiovascular death Heart failure Revascularization Non fatal stroke Non fatal MI Cancer Serious adverse event stroke (fatal and non fatal)  myocardial infarction (fatal and non fatal)  Death from any cause or hospitalization for any reason hospitalisation for heart failure Cough  Sudden death  cardiac death cardiovascular events cardiovascular events death from cardiovascular causes or hospitalization for cardiovascular causes cancer related death  Hypotension  Adverse events leading to treatment discontinuation angiodema Diabetes onset  macrovascular events  microvascular events  retinopathy  Hospitalization for any reason cardiovascular death, MI, stroke Hyperkalaemia  death or cardiovascular hospitalization  Cardiovascular death or hospital admission for CHF  hypertension Death related to diabetes  vision loss  renal death  lung cancer  breast cancer  prostate cancer     
Candesartanheart failure, in all type of patients vs placeboNSNS--NSNS--------NS by 28% NS------ by 130% -NS----NS- by 535% - by 130% by 18% -------
Candesartanheart failure, in all type of patients vs ACE inhibitor onlyNSNS-- by 32% ---------NSNS-------NS-NS----NS- by 387% - by 91% --------
Candesartanheart failure, in all type of patients vs enalaprilNSNS------------NSNS-------NS------NS------------
Candesartanheart failure, in patients previously untreated with ACE inhibitors vs placeboNSNS-----------------------------------------
Candesartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor onlyNSNS-- by 32% ---------NSNS-------NS-NS----NS- by 387% - by 92% --------
Candesartanheart failure, in patients intolerant to ACE inhibitors vs placeboNSNS--NSNS--------NS by 28% NS------ by 312% -NS----NS- by 535% - by 130% by 18% -------
Candesartanheart failure, in patients with preserved-LVEF heart failure vs placebo-------------------------------------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs controlNSNS----NS------------------------------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs conventional treatmentNSNS---NSNS----- by 27% NS------------ by 61% ----------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placeboNSNS-NS-NS----NS-NSNS----NSNSNS-----NS----------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs usual care-------------------------------------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs amlodipineNSNS----NS-----NSNS------------ by 36% ----------------
Candesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs hydrochlorothiazideNSNS-NS-NS------NSNS-----NSNS-----NS----------------
Candesartanmiscellaneous, in all type of patients vs controlNSNS----NS------------------------------------
Candesartanmiscellaneous, in all type of patients vs conventional treatmentNSNS---NSNS----- by 27% NS------------ by 61% ----------------
Candesartanmiscellaneous, in all type of patients vs placeboNSNS-NS-NS----NSNSNSNS----NSNSNS-----NS---------NS------
Candesartanmiscellaneous, in all type of patients vs amlodipineNSNS----NS-----NSNS------------ by 36% ----------------
Candesartanmiscellaneous, in all type of patients vs hydrochlorothiazideNSNS-NS-NS------NSNS-----NSNS-----NS----------------
Candesartanpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS-NS-NS----NS-NSNS----NSNSNS-----NS----------------
Olmesartandiabetes type 2, in all type of patients vs placeboNSNS--- by 312% --NSNS-----------------NS---------------
Olmesartanmiscellaneous, in all type of patients vs placeboNSNS--- by 312% --NSNS-----------------NS---------------
Telmisartanheart failure, in all type of patients vs enalaprilNSNS--NS-----------NS--------------------------
Telmisartanheart failure, in patients already receiving ACE inhibitor vs enalaprilNSNS--NS-----------NS--------------------------
Telmisartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placeboNSNS---NS----NS-NSNS-----NSNS-----NS-------------NS--
Telmisartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs EnalaprilNSNS---NS------NSNS-----------------------------
Telmisartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs RamiprilNSNS---NS------NSNS-----------------------------
Telmisartanmiscellaneous, in all type of patients vs placeboNSNS-NS-NS-NS--NS-NSNS--NS-- by 8% by 8% --NSNSNSNS----NS--------NS--
Telmisartanmiscellaneous, in all type of patients vs ramiprilNSNS-NS-NS-NS----NS--- by 74% --NSNS-- by 54% NS by 60% -----------------
Telmisartanpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS-NS-NS-NS--NS-NSNS--NS-- by 8% by 8% --NSNSNSNS----NS--------NS--
Telmisartanpatients at high risk for cardiovascular events, in all type of patients vs ramiprilNSNS-NS-NS-NS----NS--- by 74% --NSNS-- by 54% NS by 60% -----------------
Telmisartanpatients at high risk for cardiovascular events, in patients intolerant to ACE inhibitors vs placeboNSNS-NS-NS-NS----NS---NS--NSNS--NSNSNS-----NS-----------
Valsartanacute myocardial infarction, in all type of patients vs ACE inhibitor onlyNSNS---NS-------------------------------------
Valsartanacute myocardial infarction, in all type of patients vs CaptoprilNSNS---NS-------------------------------------
Valsartanheart failure, in all type of patients vs no valsartan-------------------------------------------
Valsartanheart failure, in all type of patients vs placeboNSNS--NS--------------------------------------
Valsartanheart failure, in all type of patients vs ACE inhibitor onlyNSNS-- by 46% ---------- by 24% -------NS--------NS- by 401% --------
Valsartanheart failure, in all type of patients vs enalaprilNSNS--NS--------------------------------------
Valsartanheart failure, in all type of patients vs LisinoprilNSNS--NS--------------------------------------
Valsartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor onlyNSNS-- by 46% ---------- by 24% -------NS--------NS- by 401% --------
Valsartanheart failure, in patients already receiving ACE inhibitor vs enalaprilNSNS--NS--------------------------------------
Valsartanheart failure, in patients previously untreated with ACE inhibitors vs placeboNSNS--NS--------------------------------------
Valsartanheart failure, in patients previously untreated with ACE inhibitors vs LisinoprilNSNS--NS--------------------------------------
Valsartanheart failure, in patients with preserved-LVEF heart failure vs no valsartan-------------------------------------------
Valsartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs CaptoprilNSNS---NS------NSNS-----------------------------
Irbesartandiabetes type 2, in all type of patients vs placebo---------------------------- by 70% --------------
Irbesartandiabetes type 2, in all type of patients vs amlodipineNSNS-----------------NSNS------- by 23% ----------NS---
Irbesartanheart failure, in all type of patients vs ACE inhibitor onlyNSNS-----------------------------------------
Irbesartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor onlyNSNS-----------------------------------------
Irbesartanheart failure, in patients with preserved-LVEF heart failure vs placeboNSNS---NS---------NS--------------NS--NS-NS-------
Irbesartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placeboNSNS-NS-NSNS-----NSNS-----------------------------
Irbesartanmiscellaneous, in all type of patients vs placeboNSNS-NS-NSNS-----NSNS-----------------------------
Losartanacute myocardial infarction, in all type of patients vs CaptoprilNSNS-- by 48% NS---------NS by 75% NS-----NS- by 72% -----------------
Losartandiabetes type 2, in all type of patients vs placeboNSNS-------------------------- by 21% ----------NS---
Losartanheart failure, in all type of patients vs losartan 50mgNSNS--NS--------- by 10% by 13% -------NS-NS------NSNSNS--------
Losartanheart failure, in all type of patients vs placebo by 72% by 72% -----------------------------------------
Losartanheart failure, in all type of patients vs ACE inhibitor onlyNSNS-----------------------------------------
Losartanheart failure, in all type of patients vs captoprilNSNS-- by 41% NS--------NSNS by 96% NS-----NS-NS----NS-NS-NS--------
Losartanheart failure, in all type of patients vs enalaprilNSNS--NS--------------------------------------
Losartanheart failure, in patients already receiving ACE inhibitor vs ACE inhibitor onlyNSNS-----------------------------------------
Losartanheart failure, in patients already receiving ACE inhibitor vs enalaprilNSNS--NS--------------------------------------
Losartanheart failure, in patients previously untreated with ACE inhibitors vs captoprilNSNS-- by 41% NS--------NSNS by 96% NS-----NS-NS----NS-NS-NS--------
Losartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs placeboNSNS---NS by 29% -----NSNS-----------------------------
Losartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs CaptoprilNSNS---NS------NSNS-----------------------------
Losartanhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs atenololNSNS-NS-NSNS---NS- by 25% NS----- by 14% by 14% -NS--- by 25% ------------- by 141% --
Losartanmiscellaneous, in all type of patients vs placeboNSNS---NS by 29% -----NSNS-----------------------------
Losartanmiscellaneous, in all type of patients vs atenololNSNS-NS-NSNS---NS- by 25% NS----- by 14% by 14% -NS--- by 25% ------------- by 141% --
Losartanpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS---NS by 29% -----NSNS-----------------------------
Losartanpatients at high risk for cardiovascular events, in all type of patients vs atenololNSNS-NS-NSNS---NS- by 25% NS----- by 14% by 14% -NS--- by 25% ------------- by 141% --
Captoprilhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs CaptoprilNSNS---NS------NSNS-----------------------------
Ramiprilhypertension, in all diseases requiring ACEi (HF, CHD, HT,...) vs RamiprilNSNS---NS------NSNS-----------------------------
Ramiprilmiscellaneous, in all type of patients vs ramiprilNSNS-NS-NS-NS----NS---NS--NSNS-- by 175% by 20% NS-----------------
Ramiprilmiscellaneous, in all type of patients vs telmisartanNSNS-NS-NS-NS----NS--- by 323% --NSNS-- by 78% by 28% NS-----------------
Ramiprilpatients at high risk for cardiovascular events, in all type of patients vs ramiprilNSNS-NS-NS-NS----NS---NS--NSNS-- by 175% by 20% NS-----------------
Ramiprilpatients at high risk for cardiovascular events, in all type of patients vs telmisartanNSNS-NS-NS-NS----NS--- by 323% --NSNS-- by 78% by 28% NS-----------------

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons